Biophysics of Drug Interactions with Viral Episomes
药物与病毒附加体相互作用的生物物理学
基本信息
- 批准号:8646850
- 负责人:
- 金额:$ 36.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-05-01 至 2016-04-30
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAffinityAntiviral AgentsBehaviorBenchmarkingBindingBinding SitesBiological AssayBiophysicsBlood capillariesCalibrationCalorimetryCancer EtiologyCapillary ElectrophoresisCell Culture TechniquesCell NucleusCellsCollaborationsComplementComplexConfocal MicroscopyContractsDNADNA BindingDNA SequenceDataData AnalysesDevelopmentDissociationDrug InteractionsDyesEpisomeFlow CytometryFluorescenceFluorescence AnisotropyFluorescence MicroscopyGenomeHPV-High RiskHigh-Risk CancerHumanHuman Papilloma Virus VaccineHuman PapillomavirusHuman papilloma virus 31Human papillomavirus 16Human papillomavirus 18Hydroxyl RadicalImageIn VitroInterruptionInvestigationLife Cycle StagesLinkLiteratureLocationMaintenanceMalignant neoplasm of cervix uteriMammalian CellMarketingMeasurementMeasuresMedicalMethodsModelingMolecular ModelsMolecular and Cellular BiologyMorphologic artifactsNuclearNylonsPharmaceutical PreparationsPositioning AttributePreparationPublishingResolutionRiskShapesSiteSite-Directed MutagenesisSocietiesSolutionsSolventsSpecificitySpectrum AnalysisStructureStructure-Activity RelationshipStudy modelsSurfaceSurface Plasmon ResonanceSynthesis ChemistryTestingVaccinationViralViral GenomeVirus DiseasesWorkbasecalf thymus DNAcapillarycervical cancer preventionfightingin vivointerestkeratinocytemolecular modelingpre-clinicalpreferencepublic health relevancetime usetissue/cell cultureuptakeviral DNAvirologyvirus episome maintenance
项目摘要
DESCRIPTION (provided by applicant): Antiviral compounds for high-risk, cancer-causing human papillomavirus (HPV) are extremely important even though anti-HPV vaccines are on the market. The proposed work determines the biophysics of interactions between antiviral polyamides (PAs) and their viral DNA targets, in order to determine the mechanism of action. The scope has been expanded from anti-HPV16 compounds to new anti-HPV compounds active against three cancer-causing viral subtypes. Active compounds eliminate viral episomes from human cell and tissue culture; they are potential drugs for the prevention of cervical cancer after HPV has been contracted. PAs having the same apparent DNA-binding preferences show dramatically different antiviral activities. It is proposed that a fundamental biophysical explanation of this behavior exists, one that goes beyond the known rules for PA-DNA interactions. Therefore, collaboration has begun around biophysical spectroscopy, DNA binding/footprinting assays, synthetic chemistry, virology and cellular-molecular biology. The aims are: Aim 1 Determine the binding position and affinity on the HPV16 genome of active PAs by footprinting the viral DNA as a function of PA concentration. The genome will be analyzed as overlapping 500 bp sequences using capillary electrophoresis and hydroxy radical footprinting. Binding constants determined for long DNA fragments will be compared with those from simpler models (minimal double-stranded or hairpin DNA). Independent physical methods such as fluorescence anisotropy (in competition binding studies), isothermal calorimetry and surface plasmon resonance will allow benchmarking against the literature and avoid artifacts. Aim 2 Footprint the HPV18 genome in vitro with antiviral PAs. Identify related binding sites for both HPV16 and 18. Carry out NMR structural work on DNA sequences of importance to both HPV16 and 18 as bound to active PAs; use NMR structural results as the basis for molecular modeling of additional interactions. Aim 3 Footprint active PAs on the HPV16 and 18 genomes in vivo in human cell culture. Examine the genomes using approximately 500 bp fragments generated by PCR that overlap to cover all sequence space. Determine experimental conditions and provide absolute binding constants with the aid of PA concentrations in cells measured by confocal and flow cytometry methods. Measure viral DNA concentrations vs. time using QPCR to make sure in vivo footprinting conditions are suitable. Identify structure-dependent uptake of PAs, potentially explaining why some isomeric PAs range from highly active to inactive antiviral agents. As an additional test of conclusions from footprinting, the site-directed mutagenesis of HPV18 sites identified during footprinting of antiviral PAs will help determine the importance of specific PA binding sites to the mechanism of antiviral action and viral episome maintenance. Provide new rules for interruption by polyamides of the high-risk HPV viral life cycle.
描述(由申请人提供):尽管市场上已有抗 HPV 疫苗,但针对高风险、致癌的人乳头瘤病毒 (HPV) 的抗病毒化合物仍然极其重要。拟议的工作确定了抗病毒聚酰胺 (PA) 与其病毒 DNA 靶标之间相互作用的生物物理学,以确定作用机制。范围已从抗 HPV16 化合物扩展到对三种致癌病毒亚型具有活性的新型抗 HPV 化合物。活性化合物消除人体细胞和组织培养物中的病毒游离体;它们是感染 HPV 后预防宫颈癌的潜在药物。 具有相同的明显 DNA 结合偏好的 PA 表现出显着不同的抗病毒活性。有人提出对这种行为存在一种基本的生物物理学解释,这种解释超出了 PA-DNA 相互作用的已知规则。因此,围绕生物物理光谱学、DNA 结合/足迹测定、合成化学、病毒学和细胞分子生物学的合作已经开始。目标是: 目标 1 通过将病毒 DNA 足迹作为 PA 浓度的函数,确定活性 PA 在 HPV16 基因组上的结合位置和亲和力。将使用毛细管电泳和羟基自由基足迹法将基因组分析为重叠的 500 bp 序列。长 DNA 片段确定的结合常数将与更简单模型(最小双链或发夹 DNA)的结合常数进行比较。独立的物理方法,例如荧光各向异性(在竞争结合研究中)、等温量热法和表面等离子体共振将允许根据文献进行基准测试并避免伪影。目标 2 使用抗病毒 PA 在体外足迹追踪 HPV18 基因组。确定 HPV16 和 18 的相关结合位点。对 HPV16 和 18 与活性 PA 结合的重要 DNA 序列进行 NMR 结构研究;使用 NMR 结构结果作为其他相互作用的分子建模的基础。目标 3 在人类细胞培养物中体内足迹 HPV16 和 18 基因组上的活性 PA。使用 PCR 生成的约 500 bp 片段检查基因组,这些片段重叠以覆盖所有序列空间。确定实验条件并借助共聚焦和流式细胞术方法测量的细胞中 PA 浓度提供绝对结合常数。使用 QPCR 测量病毒 DNA 浓度与时间的关系,以确保体内足迹条件合适。确定 PA 的结构依赖性摄取,可能解释为什么某些异构 PA 的抗病毒药物活性从高活性到无活性。作为对足迹分析结论的另一项测试,在抗病毒 PA 足迹分析过程中确定的 HPV18 位点定点突变将有助于确定特定 PA 结合位点对于抗病毒作用和病毒附加体维持机制的重要性。提供聚酰胺中断高危 HPV 病毒生命周期的新规则。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Interactions of two large antiviral polyamides with the long control region of HPV16.
- DOI:10.1016/j.biochi.2016.04.022
- 发表时间:2016-08
- 期刊:
- 影响因子:3.9
- 作者:Vasilieva E;Niederschulte J;Song Y;Harris GD Jr;Koeller KJ;Liao P;Bashkin JK;Dupureur CM
- 通讯作者:Dupureur CM
Thermodynamics and site stoichiometry of DNA binding by a large antiviral hairpin polyamide.
- DOI:10.1016/j.biochi.2018.11.013
- 发表时间:2019-02
- 期刊:
- 影响因子:3.9
- 作者:Yang Song;Jacquelyn Niederschulte;Kristin N. Bales;J. Bashkin;C. M. Dupureur
- 通讯作者:Yang Song;Jacquelyn Niederschulte;Kristin N. Bales;J. Bashkin;C. M. Dupureur
Heterogeneous dynamics in DNA site discrimination by the structurally homologous DNA-binding domains of ETS-family transcription factors.
- DOI:10.1093/nar/gkv267
- 发表时间:2015-04-30
- 期刊:
- 影响因子:14.9
- 作者:He G;Tolic A;Bashkin JK;Poon GM
- 通讯作者:Poon GM
What is the antiviral potential of pyrrole-imidazole polyamides?
- DOI:10.4155/fmc.15.120
- 发表时间:2015-01-01
- 期刊:
- 影响因子:4.2
- 作者:He, Gaofei;Bashkin, James K.
- 通讯作者:Bashkin, James K.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James K. Bashkin其他文献
Polyamides pour le traitement du virus du papillome humain
人乳头状病毒性状聚酰胺
- DOI:
- 发表时间:
2007 - 期刊:
- 影响因子:0
- 作者:
James K. Bashkin;C. Fisher;Kevin J. Koeller - 通讯作者:
Kevin J. Koeller
James K. Bashkin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James K. Bashkin', 18)}}的其他基金
Biophysics of Drug Interactions with Viral Episomes
药物与病毒附加体相互作用的生物物理学
- 批准号:
8259751 - 财政年份:2010
- 资助金额:
$ 36.11万 - 项目类别:
Biophysics of Drug Interactions with Viral Episomes
药物与病毒附加体相互作用的生物物理学
- 批准号:
7987715 - 财政年份:2010
- 资助金额:
$ 36.11万 - 项目类别:
Biophysics of Drug Interactions with Viral Episomes
药物与病毒附加体相互作用的生物物理学
- 批准号:
8063932 - 财政年份:2010
- 资助金额:
$ 36.11万 - 项目类别:
Biophysics of Drug Interactions with Viral Episomes
药物与病毒附加体相互作用的生物物理学
- 批准号:
8453365 - 财政年份:2010
- 资助金额:
$ 36.11万 - 项目类别:
HYDROLYTIC CLEAVAGE OF RNA BY METAL COMPLEXES, FUNDAMENTAL STUDY IN CATALYSIS
金属配合物对 RNA 的水解裂解,催化基础研究
- 批准号:
6665799 - 财政年份:2002
- 资助金额:
$ 36.11万 - 项目类别:
MECHANISM & CHARGE CONTROL OF METAL CATALYZED RNA TRANSESTERIFICATION
机制
- 批准号:
6665800 - 财政年份:2002
- 资助金额:
$ 36.11万 - 项目类别:
HYDROLYTIC CLEAVAGE OF RNA BY METAL COMPLEXES, FUNDAMENTAL STUDY IN CATALYSIS
金属配合物对 RNA 的水解裂解,催化基础研究
- 批准号:
6486679 - 财政年份:2001
- 资助金额:
$ 36.11万 - 项目类别:
MECHANISM & CHARGE CONTROL OF METAL CATALYZED RNA TRANSESTERIFICATION
机制
- 批准号:
6486680 - 财政年份:2001
- 资助金额:
$ 36.11万 - 项目类别:
HYDROLYTIC CLEAVAGE OF RNA BY METAL COMPLEXES, FUNDAMENTAL STUDY IN CATALYSIS
金属配合物对 RNA 的水解裂解,催化基础研究
- 批准号:
6336749 - 财政年份:2000
- 资助金额:
$ 36.11万 - 项目类别:
MECHANISM & CHARGE CONTROL OF METAL CATALYZED RNA TRANSESTERIFICATION
机制
- 批准号:
6336750 - 财政年份:2000
- 资助金额:
$ 36.11万 - 项目类别:
相似国自然基金
抗原非特异性B细胞进入生发中心并实现亲和力成熟的潜力与调控机制
- 批准号:32370941
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
面向免疫疗法标志物识别的基于多特征融合的肽与MHC亲和力预测研究
- 批准号:62302277
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于计算生物学技术小分子农兽药残留物驼源单域抗体虚拟筛选与亲和力成熟 -以内蒙古阿拉善双峰驼为例
- 批准号:32360190
- 批准年份:2023
- 资助金额:34 万元
- 项目类别:地区科学基金项目
基于胞内蛋白亲和力标记策略进行新型抗类风湿性关节炎的选择性OGG1小分子抑制剂的发现
- 批准号:82304698
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
面向多场景应用的药物-靶标结合亲和力预测研究
- 批准号:62371403
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 36.11万 - 项目类别:
Four-dimensional Adhesion Frequency Assay for Full Profiling of Receptor-ligand Interactions on Cells
四维粘附频率测定,全面分析细胞上受体-配体相互作用
- 批准号:
10707983 - 财政年份:2022
- 资助金额:
$ 36.11万 - 项目类别:
Developing Broad-Spectrum Antivirals Targeting Coronavirus Replicase and Helicase
开发针对冠状病毒复制酶和解旋酶的广谱抗病毒药物
- 批准号:
10513685 - 财政年份:2022
- 资助金额:
$ 36.11万 - 项目类别:
Developing three-dimensional antisense oligonucleotide drugs against COVID-19
开发针对COVID-19的三维反义寡核苷酸药物
- 批准号:
10645137 - 财政年份:2021
- 资助金额:
$ 36.11万 - 项目类别:
Developing three-dimensional antisense oligonucleotide drugs against COVID-19
开发针对COVID-19的三维反义寡核苷酸药物
- 批准号:
10453620 - 财政年份:2021
- 资助金额:
$ 36.11万 - 项目类别: